PDL BioPharma Inc

PDL BioPharma — Q4 2016 Earnings Presentation

14 slides from PDL BioPharma's earnings presentation, Mar 1, 2017

  1. Slide 1: Fourth Quarter and Year-End 2016 Financial Results Conference Call

    PDL Fourth Quarter and Year-End 2016 Financial Results Conference Call March 1, 2017

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements, including PDL’s expectations with respect to its future royalty revenues, expenses, net income, and cash provided by operating activities. Each of these forward-looking statements involves risks and uncertainties. Actu

  3. Slide 3: Focus: Long-term Value

    Focus: Long-term Value o Focused on growth in order to continue value creation for shareholders. o Have committed over $1.4 billion and deployed over $1.1 billion since launching this strategy in 2012. o Expansion in our strategy with our first significant equity transaction with Noden Pharma DAC in

  4. Slide 4: Noden Background

    Noden Background o Noden Pharma = Formed for the purpose of acquiring specialty pharma products. = Domiciled in Ireland and has operating companies in US and EU. = Recruited strong and seasoned management team many of whom are in place. = PDL holds three of five board seats.

  5. Slide 5: Tekturna, Noden's Flagship Product

    Tekturna, Noden’s Flagship Product o Tekturna, for the treatment of hypertension = Tekturna and Tekturna HCT (known as Rasilez® in EU) consist of the direct renin inhibitor, aliskiren, as a monotherapy and as a fixed-dose combination with the diuretic hydrochlorothiazide, respectively. = Tekturna is

  6. Slide 6: Transitioning from Novartis Commercialization

    Transitioning from Novartis Commercialization o US = Noden USA fielded a contract sales force of ~40 reps and 4 district managers, dedicated solely to these products, in late February 2017. = Novartis distributed through September 30, 2016 and Noden received a transfer of profit. = Noden USA assumed

  7. Slide 7: Royalty & Debt Investments Current Deals

    16 Royalty & Debt Investments 11 Current Deals Rovalty Acquisition Rovalty Acquisition Rovalty Acquisition Senior Secured Rovaty Acauisitin | [_ Rovaty Acauisition Financing eee ne harmaceuticals ine SRA $9,500,000 $65,000,000 Up to$140,000,000 $40,000,000 $66,600,000 $15,500,000 “uly 2046 september

  8. Slide 8: Concluding ARIAD Transaction

    Concluding ARIAD Transaction o Synthetic royalty transaction signed in July 2015. o Have funded $100 million. o Acquisition of ARIAD by Takeda closed last month. o PDL exercised put option which will result in repayment of 1.2x multiple of the $100 million, less royalty payments received by PDL thus

  9. Slide 9: Foreclosure on Direct Flow Medical

    Foreclosure on Direct Flow Medical o Senior secured financing transaction signed in November 2013. o DFM shut down operations in December 2016 due to unexpected change in funding. o PDL initiated foreclosure proceedings in January 2017 resulting in PDL’s ownership of certain DFM assets through wholl

  10. Slide 10: Wellstat Diagnostics Litigation Continues

    10 Wellstat Diagnostics Litigation Continues o Background Point of care diagnostics company. $44 million hybrid debt-royalty transaction but PDL advanced additional sums to maintain asset during sale process. Owners of company diverted funds in violation of the terms of the loan contract and have si

  11. Slide 11: LENSAR Reacquires Assets

    LENSAR Reacquires Assets o Background = Medtech company with high speed laser technology used in cataract surgery, among other procedures. = $49 million debt structure. = Subsidiary of Alphaeon acquired substantially all of LENSAR’s assets in late 2015 in return for assuming PDL’s debt and shares of

  12. Slide 12: Fourth Quarter 2016 Financials

    Fourth Quarter 2016 Financials Three Months Ended December 31. Twelve Months Ended December 31, (in thousands, except per share amounts) (unaudited) 2016 2015 2016 2015 Royalties from Queen et al. patents $15,513. _$ 121,240 _§ 166,158 _$ 485,156 Royalty rights - change in fair value 28,068. 49,069

  13. Slide 13: Fourth Quarter 2016 Financials

    Fourth Quarter 2016 Financials Condensed consolidated balance sheet (unaudited) Cash, cash equivalents and investments Total notes receivable Total royalty rights - at fair value Total assets Total term loan payable Convertible notes payable Total stockholders's equity December 31, December 31, 2016

  14. Slide 14: Question and Answer Session

    PDL Question and Answer Session

PDL BioPharma — Q4 2016 Earnings Presentation on 6ix